Fate Therapeutics

Fate develops programmed cellular immunotherapies for the treatment of metastatic cancer, traumatic injury and degenerative diseases.

Business Model:

Revenue: $69M

Employees: 201-500

Detailed Fate Therapeutics Information

Geographic Data

Fate Therapeutics headquarters map

Address: 3535 General Atomics Court

City: San Diego

State: CA

Zip: 92121

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$432M

Raised Total:

$366M

Metrics

2,454,874Website Global Rank

7,399Website Monthly Traffic

Twitter Followers

Description

Fate develops programmed cellular immunotherapies for the treatment of metastatic cancer, traumatic injury and degenerative diseases.

Contact Phone:
+18588751800

Contact Email:

Fate Therapeutics went public on 10/4/2013 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
10/4/2013

Ticker Symbol:
FATE

IPO Price:
$6/share

Amount Raised:
$40M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
7/2014 Post-IPO Debt 1 $20M Silicon Valley Bank
Silicon Valley Bank
8/2012 Venture Round $9.2M
4/2011 Debt Financing $1M
11/2009 Series B 6 $30M Venrock
Sanofi Ventures
Polaris Partners
OVP Venture Partners
Astellas Venture Management
ARCH Venture Partners
Venrock
Sanofi Ventures
Polaris Partners
OVP Venture Partners
Astellas Venture Management
ARCH Venture Partners
11/2007 Series A 4 $12M Venrock
Polaris Partners
OVP Venture Partners
ARCH Venture Partners
Venrock
Polaris Partners
OVP Venture Partners
ARCH Venture Partners
5/2015 Post-IPO Equity $32M
12/2017 Post-IPO Equity $42.9M
12/2016 Post-IPO Equity $56.7M
6/2020 Post-IPO Equity $201.3M
1/2021 Post-IPO Equity $432M
8/2016 Post-IPO Equity $10.3M
5/2011 Series B 5 $36M Venrock
Polaris Partners
OVP Venture Partners
Astellas Venture Management
ARCH Venture Partners
Venrock
Polaris Partners
OVP Venture Partners
Astellas Venture Management
ARCH Venture Partners
5/2015 Post-IPO Equity $8M
9/2019 Post-IPO Equity $173M
9/2018 Post-IPO Equity $143.8M
11/2016 Post-IPO Equity $56.7M
9/2013 IPO $40M
2/2018 Grant 1 $4M California Institute for Regenerative Medicine
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine
Announced Date Name Price
4/2010 Verio Therapeutics

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research